X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (53) 53
oncology (53) 53
breast cancer (50) 50
female (50) 50
index medicus (44) 44
middle aged (35) 35
cancer (34) 34
adult (32) 32
chemotherapy (32) 32
breast neoplasms - drug therapy (29) 29
breast neoplasms - pathology (23) 23
treatment outcome (23) 23
aged (22) 22
surgery (21) 21
trastuzumab (21) 21
medicine & public health (18) 18
care and treatment (17) 17
neoadjuvant therapy (17) 17
adjuvant treatment (16) 16
therapy (16) 16
research (15) 15
risk factors (15) 15
chemotherapy, adjuvant (14) 14
clinical trials (13) 13
disease-free survival (13) 13
follow-up studies (13) 13
breast neoplasms - mortality (12) 12
cancer therapies (12) 12
antineoplastic combined chemotherapy protocols - therapeutic use (11) 11
breast neoplasms - genetics (11) 11
breast neoplasms - surgery (11) 11
neoplasm staging (11) 11
obstetrics & gynecology (11) 11
prognosis (11) 11
surgical oncology (11) 11
survival (11) 11
paclitaxel (10) 10
analysis (9) 9
hematology, oncology and palliative medicine (9) 9
pathological complete response (9) 9
women (9) 9
antimitotic agents (8) 8
antineoplastic agents (8) 8
breast neoplasms - metabolism (8) 8
cyclophosphamide (8) 8
drug therapy (8) 8
efficacy (8) 8
health aspects (8) 8
internal medicine (8) 8
medicine, general & internal (8) 8
preoperative chemotherapy (8) 8
tumors (8) 8
abridged index medicus (7) 7
adjuvant chemotherapy (7) 7
doxorubicin (7) 7
genes (7) 7
pertuzumab (7) 7
prospective studies (7) 7
receptor, erbb-2 - analysis (7) 7
anthracyclines (6) 6
antibodies, monoclonal, humanized - administration & dosage (6) 6
article (6) 6
breast (6) 6
breast neoplasms - therapy (6) 6
combination (6) 6
erbb-2 protein (6) 6
male (6) 6
medical research (6) 6
mutation (6) 6
neoadjuvant chemotherapy (6) 6
open-label (6) 6
ovarian-cancer (6) 6
product development (6) 6
radiation therapy (6) 6
randomized controlled trials as topic (6) 6
receptor, erbb-2 - metabolism (6) 6
risk (6) 6
safety (6) 6
survival analysis (6) 6
aged, 80 and over (5) 5
antineoplastic agents - administration & dosage (5) 5
antineoplastic agents - therapeutic use (5) 5
cancer patients (5) 5
drug administration schedule (5) 5
epidermal growth factor (5) 5
genetic aspects (5) 5
her2 (5) 5
lapatinib (5) 5
metastases (5) 5
multicenter (5) 5
oncology, experimental (5) 5
patient outcomes (5) 5
patients (5) 5
plus (5) 5
retrospective studies (5) 5
surgical adjuvant breast (5) 5
trial (5) 5
young adult (5) 5
1st-line treatment (4) 4
antibodies, monoclonal, humanized (4) 4
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 10, pp. 1137 - 1146
Journal Article
Lancet, The, ISSN 0140-6736, 2013, Volume 382, Issue 9897, pp. 1021 - 1028
Journal Article
Lancet, The, ISSN 0140-6736, 2017, Volume 389, Issue 10075, pp. 1195 - 1205
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2011, Volume 12, Issue 3, pp. 236 - 244
Journal Article
Lancet, The, ISSN 0140-6736, 2014, Volume 384, Issue 9938, pp. 164 - 172
Journal Article
Lancet, The, ISSN 0140-6736, 2012, Volume 379, Issue 9816, pp. 633 - 640
Summary Background The anti-HER2 monoclonal antibody trastuzumab and the tyrosine kinase inhibitor lapatinib have complementary mechanisms of action and... 
Internal Medicine | ADJUVANT CHEMOTHERAPY | APOPTOSIS | CELLS | WOMEN | MEDICINE, GENERAL & INTERNAL | GW572016 | ERBB2 | INHIBITOR | PLUS | Breast Neoplasms - surgery | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Diarrhea - chemically induced | Breast Neoplasms - chemistry | Antibodies, Monoclonal, Humanized - administration & dosage | Liver - drug effects | Adult | Female | Quinazolines - administration & dosage | Receptor, ErbB-2 - antagonists & inhibitors | Chemotherapy, Adjuvant | Biomarkers, Tumor - antagonists & inhibitors | Paclitaxel - administration & dosage | Antibodies, Monoclonal, Humanized - adverse effects | Drug Administration Schedule | Administration, Oral | Biomarkers, Tumor - analysis | Liver - metabolism | Paclitaxel - adverse effects | Treatment Outcome | Breast Neoplasms - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Neoadjuvant Therapy - methods | Quinazolines - adverse effects | Aged | Infusions, Intravenous | Receptor, ErbB-2 - analysis | Trastuzumab | Drug therapy | Breast cancer | Genetic aspects | Medical research | Ligands | Cytotoxicity | Mammography | Kinases | Cancer therapies | pathology | Liver | methods | Antibodies | Oral | Quinazolines | Breast Neoplasms | Tumor Markers | administration & dosage | Surgery | Paclitaxel | Neoadjuvant Therapy | Adjuvant | Monoclonal | chemistry | Administration | drug therapy | chemically induced | Intravenous | Infusions | Humanized | Antineoplastic Combined Chemotherapy Protocols | Diarrhea | drug effects | Biological | analysis | Kirurgi | antagonists & inhibitors | Chemotherapy | Receptor | adverse effects | metabolism | Cancer and Oncology | therapeutic use | Cancer och onkologi | erbB-2
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 3, pp. 345 - 356
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 7, pp. 609 - 618
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 7, pp. 747 - 756
Journal Article
Lancet, The, ISSN 0140-6736, 2009, Volume 373, Issue 9674, pp. 1532 - 1542